FOCUS ON ...
The general objective of the team’s research project is to evaluate the complex nature of immune mechanisms induced during protozoan parasite (co)infections. In the high endemic areas of the Amazonian ecosystem of the French Guyana concomitant infections by Plasmodium, Leishmania and Toxoplasma cause more chronic asymptomatic disease than acute severe illnesses. Such asymptomatic individuals develop anti-disease immunity and become parasite reservoirs. The workprogram is based on a “one health” strategy capitalizing on the strength and the multidisciplinary expertise of the team members (clinicians working on the field in FG, molecular parasitology, epidemiology and immunology). The specific aims are to: 1) identify immune signatures associate to protection or pathology and 2) investigate how they are modulated by environmental factors and host multi-biome and influence the disease progression in such settings. Data obtained should allow to identify disease phenotype biomarkers and targets for diagnosis, prognosis, prevention and treatment.
The team is composed of two groups: 1) group 1 at the Institute Pasteur of Lille is leaded by S. Pied DR CNRS and 2) group 2 at the University of Guyana and Cayenne Hospital (CHAR) leaded by M. Demar, PU-PH. The team is linked to the Laboratory of Parasitology–Mycology and several medical units, including the departments of 1) infectious and tropical diseases, 2) dermatology, and 3) several health centers for remote areas of Guiana. Moreover, TBIP has ties with the Clinical Investigation Center (CIC INSERM-CIE 802 leaded by M. Nacher).
Through the weekly episodes, you will discover our different research themes from Lille and French Guyana. For this first week, zoom on Amazonian toxoplasmosis…
Our Youtube chanel
Third episode in the series dedicated to researching Covid-19. This webinar is moderated by Marie Treibert, science popularizer on the La Boîte à curiosités channel. She questions Sandrine Belouzard, virologist and CNRS researcher, who answers all questions relating to antivirals in the treatment of Covid-19. What is the difference between a vaccine and an antiviral treatment? How does an antiviral work? Who will benefit from it? Do we favor therapeutic repositioning or research for a new drug? Through definitions, a press review and an interview, this webinar takes stock of the subject.
One year after the first cases of COVID-19, researchers of the Center for Infection & Immunity of Lille present the current knowledge on SARS-CoV-2 in the context of a series of conferences organized by the Lille Research Taskforce on COVID-19, in partnership with the Society of Sciences, Agriculture and Arts of Lille.
Researchs against Covid-19 at the Institut Pasteur in Lille.
Coronaviruses, specificities and prospects for treatment by Jean Dubuisson, director of the Center for Infection & Immunity of Lille
More than 60 diseases can be transmitted to humans by rats. Among them, Plague, believed to be a disease of the past, has never been eradicated ...
"While bats are not to blame for everything, they have played a role in the transmission of at least 11 viruses" ...
COVID-19: Jean Dubuisson tells us about ANTI-CoV, a project supported by the FRM